Immune Mediated Articles & Analysis: Older
33 news found
It was long thought to be undetectable by the cell-mediated immune system. However, recent studies have shown that EBNA1 can be presented to both CD4+ and CD8+ T cells, making it a potential new target for EBV-associated cancer immunotherapy. ...
The results were published in the article “A Personal COVID-19 Dendritic Cell Vaccine Made at Point-of-Care: Feasibility, Safety, and Antigen-Specific Cellular Immune Responses” in the journal Human Vaccines & Immunotherapeutics. ...
It was previously thought to have a purely structural role, similar to the function of phosphatidylcholine, through intermolecular interactions mediated by the 2-amide group, the 3-hydroxy group and the 4,5-trans double bond of the sphingoid base. ...
The paper entitled “A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity” shows that Ziphius’ multi-antigenic self-amplifying RNA COVID-19 vaccine candidate induces a potent humoral and cellular ...
IO-106 is the third development candidate arising from Immune-Onc’s pioneering pipeline of myeloid checkpoint inhibitors, a new class of immunotherapy that aims to overcome immune resistance in cancer The Company will present a scientific poster at the Society for Immunotherapy of Cancer (SITC) Tumor Immune Microenvironment: A Holistic ...
CB-011 is an allogeneic anti-BCMA CAR-T cell therapy immune cloaked to blunt both T- and NK-mediated immune cell rejection, enabling more durable antitumor activity -- Data support an expected Investigational New Drug (IND) application submission in 2022 for CB-011, Caribou’s second allogeneic cell therapy product candidate -- Caribou ...
Cipla also recently launched a biosimilar for the treatment of immune-mediated inflammatory disease. According to the Cancer Alliance report CA03/2021, South Africa faces a crisis in terms of affordable access to medicines, particularly in the treatment of cancer. ...
(Nasdaq: SGMO), a genomic medicine company, today announced dosing of the first patient in the Phase 1/2 STEADFAST clinical study evaluating TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living ...
Over the past decade, immunotherapy has become one of the mainstays of cancer treatment, thanks in large part to monoclonal antibodies targeting the immune checkpoint protein PD-1 or its major ligand PD-L1 (mAbs). Due to abnormal immune surveillance mediated by immune checkpoints, tumor cells develop immune ...
Cytovale, a medical diagnostics company focused on providing rapid and insightful tools to improve early detection of fast-moving and immune-mediated diseases, today announced a new study on its investigational IntelliSep test has been published in the peer-reviewed journal PLOS ONE. ...
(Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a research and evaluation collaboration with The Laura and Isaac Perlmutter Cancer Center, a National Cancer Institute designated Comprehensive Cancer Center ...
Cytovale, a medical diagnostics company focused on providing rapid and insightful tools to improve early detection of fast-moving and immune-mediated diseases, has received additional funding from Biomedical Research and Development Authority (BARDA) to help advance the company’s 10-minute IntelliSep sepsis risk stratification test towards commercial ...
Our off-the-shelf GammabodyTM, LAVA-1207, has preclinically demonstrated dose dependent, potent and selective anti-cancer activity against PSMA-expressing tumors through the triggering of gamma delta T cell-mediated immunity,” said Benjamin Winograd, M.D., Ph.D., chief medical officer, LAVA Therapeutics. ...
“With the proteolytic shedding of the α1 and α2 domains of MICA/B being recognized as a common tumor escape mechanism, we are encouraged that our novel CAR design, which uniquely targets the α3 domain of MICA/B, has shown the potential to overcome shedding and restore NK and T cell-mediated tumor immunity. We look forward to treating ...
“Sanofi’s collaboration with Exscientia aims to transform how we discover and develop new small molecule medicines for cancer and immune-mediated diseases. Application of sophisticated AI and machine learning methods will not only shorten drug discovery timelines, but will also help to design higher quality and better targeted medicines for ...
Millions of years of evolution have taught our immune system how to protect against pathogens. Angany brings a novel generation of allergy immunotherapy where allergens are administered under the form of pseudo-pathogens to elicit a protective immune response. ...
” About eosinophilic esophagitis Eosinophilic esophagitis (EoE) is a rare, chronic, local immune-mediated esophageal disease, characterized clinically by symptoms related to esophageal dysfunction, and histologically by eosinophil-predominant inflammation. ...
“The amlitelimab data presented at EADV support our belief that OX40-Ligand has the potential to provide a novel approach to treating a range of immune-mediated diseases," said Naimish Patel, M.D. Head of Global Development in Immunology and Inflammation at Sanofi. ...
Although the exact cause of IBD is not entirely understood, IBD is known to involve an interaction between genes, environmental factors, and dysregulation of the immune system, resulting in chronic inflammation. The CDC estimates that IBD affects an estimated 1.3% of adults in the United States, or approximately 3 million people. About Vedanta Biosciences Vedanta Biosciences is ...
Cytovale, a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-moving and immune mediated diseases, today announced the publication of a study in the peer-reviewed journal Critical Care Explorations (CCE) evaluating its IntelliSep test as a tool in the rapid diagnosis of sepsis in the hospital emergency department ...